niacinamide and px-866

niacinamide has been researched along with px-866 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S	1

Other Studies

1 other study(ies) available for niacinamide and px-866

Article	Year
Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. Molecular pharmacology, 2013, Volume: 84, Issue:4 Topics: Animals; Cell Communication; Cell Death; Cell Line, Tumor; Drug Synergism; Female; Gonanes; Hep G2 Cells; Humans; Mice; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; Thymoma; Thymus Neoplasms; Xenograft Model Antitumor Assays	2013

Article

Year

Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.

Molecular pharmacology, 2013, Volume: 84, Issue:4

Topics: Animals; Cell Communication; Cell Death; Cell Line, Tumor; Drug Synergism; Female; Gonanes; Hep G2 Cells; Humans; Mice; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; Thymoma; Thymus Neoplasms; Xenograft Model Antitumor Assays

2013